Cargando…

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors

SIMPLE SUMMARY: In a retrospective study of patients with advanced or metastatic melanoma treated with first-line immune checkpoint inhibitors, we investigated the value of metabolic criteria, PERCIST 5 (criteria used for conventional chemotherapy), and imPERCIST5 (criteria adapted for immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivas, Alexia, Delyon, Julie, Martineau, Antoine, Blanc, Estelle, Allayous, Clara, Da Meda, Laetitia, Merlet, Pascal, Lebbé, Céleste, Baroudjian, Barouyr, Vercellino, Laetitia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264956/ https://www.ncbi.nlm.nih.gov/pubmed/35804963 http://dx.doi.org/10.3390/cancers14133190

Ejemplares similares

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma
por: Pesqué, Louise, et al.
Publicado: (2022)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases
por: Tétu, Pauline, et al.
Publicado: (2020)

Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
por: Vercellino, Laetitia, et al.
Publicado: (2022)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

Nivolumab-induced alopecia areata: A reversible factor of good prognosis?
por: Lakhmiri, Myriam, et al.
Publicado: (2018)

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study
por: HERMS, Florian, et al.
Publicado: (2022)

Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
por: Beaziz, Jessica, et al.
Publicado: (2021)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Gauci, Marie-Léa, et al.
Publicado: (2021)

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)

Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
por: Yatim, Nader, et al.
Publicado: (2021)

Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study
por: Benajiba, Lina, et al.
Publicado: (2021)

Prognostic Impact of (18)FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer
por: Groheux, David, et al.
Publicado: (2012)

Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes
por: Nguyen, Thuy Thi, et al.
Publicado: (2020)

(18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis
por: Groheux, David, et al.
Publicado: (2017)

Telomere-Associated Changes in Nuclear Architecture of Cancer-Associated Macrophage-like Cells in Liquid Biopsies from Melanoma Patients
por: Rangel-Pozzo, Aline, et al.
Publicado: (2022)

Endemic Kaposi’s Sarcoma
por: Zeinaty, Perla El, et al.
Publicado: (2023)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

(18)F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
por: Girum, Kibrom B., et al.
Publicado: (2022)

Impact des inhibiteurs de checkpoints immunitaires au cours de la COVID-19 chez les patients atteints de mélanome
por: Yatim, N., et al.
Publicado: (2021)

Effect of Point Spread Function Deconvolution in Reconstruction of Brain (18)F-FDG PET Images on the Diagnostic Thinking Efficacy in Alzheimer's Disease
por: Doyen, Matthieu, et al.
Publicado: (2021)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Atypical Muscular Sarcoidosis Involvement Revealed by (18) F-FDG PET/CT
por: Lucinian, Yousif A., et al.
Publicado: (2022)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT
por: Cottereau, Anne-Ségolène, et al.
Publicado: (2021)

Volume of the proximal half of the thoracic aorta is the most comprehensive FDG-PET/CT indicator of arterial aging throughout adulthood
por: Hurstel, Moira, et al.
Publicado: (2023)

Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
por: Amrane, Karim, et al.
Publicado: (2019)

Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
por: Capobianco, Nicolò, et al.
Publicado: (2021)

Head-to-head comparison of image quality between brain (18)F-FDG images recorded with a fully digital versus a last-generation analog PET camera
por: Salvadori, Julien, et al.
Publicado: (2019)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
por: Tétu, Pauline, et al.
Publicado: (2020)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET
por: Martineau, Patrick, et al.
Publicado: (2020)

FDG-PET in lymphoma
por: Meignan, Michel
Publicado: (2014)

PET-FDG: Impetus
por: Nanni, Cristina
Publicado: (2020)

Place of the (18)F-FDG-PET/CT in the Diagnostic Workup in Patients with Classical Fever of Unknown Origin (FUO)
por: Letertre, Simon, et al.
Publicado: (2021)

Predictive value and accuracy of [(18)F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
por: Ayati, Narjess, et al.
Publicado: (2023)

Validation of a preclinical model for assessment of drug efficacy in melanoma
por: Delyon, Julie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ddgsfb0pj0eiuqdcsq1d1srokd